ISSN: 1301-2193 E-ISSN: 1308-9846
  • Turkish Journal of
    Endocrinology and Metabolism
ORIGINAL ARTICLE

Effects of Isotretinoin Treatment on Levels of Hormones Involved in the Etiopathogenesis of Acne
İzotretinoin Tedavisinin Akne Etiyopatogenezinde Yer Alan Hormon Düzeyleri Üzerindeki Etkileri
Received Date : 01 Apr 2020
Accepted Date : 21 Jul 2020
Available Online : 31 Aug 2020
Doi: 10.25179/tjem.2020-75230 - Makale Dili: EN
Turk J Endocrinol Metab. 2020;24:237-246
Bu makale, CC BY-NC-SA altında lisanslanmış açık erişim bir makaledir.
ABSTRACT
Objective: This study was performed to measure the effect of isotretinoin treatment on hormonal responses and insulin resistance in acne patients. Material and Methods: A total of 30 acne vulgaris patients and 30 control group volunteers were examined between February 2015 and June 2015. Firstly, the basal insulin resistance and endocrine hormone levels were measured in both groups. A daily dose of 120– 150 mg/kg oral isotretinoin was administered to the patient group for three months. Following this, insulin resistance and endocrine hormone levels were re-evaluated in both groups. Results: Age, waist circumference, and body mass index were similar between the patient and control groups. Liver transaminase, low-density lipoprotein (LDL), adrenocorticotropic hormone, cortisol, 17-hydroxyprogesterone, and total testosterone levels were different in the patient group compared to the control group (p<0.05). The levels of dehydroepiandrosterone sulfate (DHEA-S), liver transaminase, LDL, and triglycerides increased after three months of isotretinoin administration (p<0.05). The changes in blood triglyceride levels were correlated with the changes in insulin growth factor-1, DHEA-S, total testosterone, progesterone, LDL, and estradiol levels (p<0.05). Conclusion: Isotretinoin might not affect pituitary gland hormones, adrenal hormones, and insulin resistance significantly. Increased blood triglyceride levels may be expected in patients whose testosterone and progesterone hormone levels are high.
ÖZET
Amaç: Bu çalışma, akne hastalarında izotretinoin tedavisinin hormonal yanıt ve insülin direnci üzerindeki etkisini ölçmek amacıyla planlanmıştır. Gereç ve Yöntemler: Şubat 2015-Haziran 2015 tarihleri arasında toplam 30 akne vulgaris hastası ve 30 gönüllü kontrol grubu incelendi. İlk olarak, her iki grupta bazal insülin direnci ve endokrin hormon düzeyleri ölçüldü. Üç ay boyunca hasta grubuna günde 120- 150 mg/kg oral izotretinoin uygulandı. Bunu takiben her iki grupta da insülin direnci ve endokrin hormon düzeyleri yeniden değerlendirildi. Bulgular: Hasta ve kontrol grubu arasında yaş, bel çevresi ve beden kitle indeksi benzerdi. Hasta grubunda karaciğer transaminazları, “low-density lipoprotein (LDL)”, adrenokortikotropik hormon, kortizol, 17-hidroksiprogesteron ve total testosteron düzeyleri kontrol grubuna göre farklıydı (p<0,05). Üç aylık izotretinoin uygulamasından sonra dihidroepiandrosteron sülfat (DHEA-S), karaciğer transaminazları, LDL ve trigliserid düzeyleri artmıştı (p<0,05). Kan trigliserid düzeylerindeki değişiklik, insülin benzeri büyüme faktörü-1, DHEA-S, total testosteron, progesteron, LDL ve östradiol düzeylerindeki değişikliklerle korele idi (p<0,05). Sonuç: İzotretinoin hipofiz bezi hormonlarını, adrenal hormonları ve insülin direncini anlamlı bir şekilde etkilemeyebilir. Testosteron ve progesteron hormon seviyeleri yüksek olan hastalarda kan trigliserid düzeylerinde artış beklenebilir.
KAYNAKLAR
  1. Arora MK, Yadav A, Saini V. Role of hormones in acne vulgaris. Clin Biochem. 2011;44:1035-1040. [Crossref]  [PubMed] 
  2. Goulden V, Stables GI, Cunliffe WJ. Prevalence of facial acne in adults. J Am Acad Dermatol. 1999;41:577-580. [Crossref]  [PubMed] 
  3. Azmahani A, Nakamura Y, McNamara KM, Sasano H. The role of androgen under normal and pathological conditions in sebaceous glands: the possibility of target therapy. Curr Mol Pharmacol. 2016;9:311-319. [Crossref]  [PubMed] 
  4. Balta I, Ekiz O, Ozuguz P, Ustun I, Karaca S, Kacar SD, Eksioglu M. Insulin resistance in patients with post-adolescent acne. Int J Dermatol. 2015;54:662-666. [Crossref]  [PubMed] 
  5. Akman A, Durusoy C, Senturk M, Koc CK, Soyturk D, Alpsoy E. Treatment of acne with intermittent and conventional isotretinoin: a randomized, controlled multicenter study. Arch Dermatol Res. 2007;299:467-473. [Crossref]  [PubMed]  [PMC] 
  6. Cooper AJ, Harris VR. Modern management of acne. Med J Aust. 2017;206:41-45. [Crossref]  [PubMed] 
  7. Karadag AS, Takci Z, Ertugrul DT, Bilgili SG, Balahoroglu R, Takir M. The effect of different doses of isotretinoin on pituitary hormones. Dermatology. 2015;230:354-359. [Crossref]  [PubMed] 
  8. Karadag AS, Ertugrul DT, Tutal E, Akin KO. Isotretinoin influences pituitary hormone levels in acne patients. Acta Derm Venereol. 2011;91:31-34. [Crossref]  [PubMed] 
  9. Goulden V, Clark SM, Cunliffe WJ. Post-adolescent acne: a review of clinical features. Br J Dermatol. 1997;136:66-70. [Crossref]  [PubMed] 
  10. Collier CN, Harper JC, Cafardi JA, Cantrell WC, Wang W, Foster KW, Elewski BE. The prevalance of acne in adults 20 years and older. J Am Acad Dermatol. 2008;58:56-59. [Crossref]  [PubMed] 
  11. Dréno B, Thiboutot D, Layton AM, Berson D, Perez M, Kang S, Global Alliance to Improve Outcomes in Acne. Large-scale international study enhances understanding of an emerging acne population: adult females. J Eur Acad Dermatol Venereol. 2015;29:1096-1106. [Crossref]  [PubMed] 
  12. Cibula D, Hill M, Vohradnikova O, Kuzel D, Fanta M, Zivny J. The role of androgens in determining acne severity in adult women. Br J Dermatol. 2000;143:399-404. [Crossref]  [PubMed] 
  13. Borgia F, Cannavò S, Guarneri F, Cannavò SP, Vaccaro M, Guarneri B. Correlation between endocrinological parameters and acne severity in adult women. Acta Derm Venereol. 2004;84:201-204. [Crossref]  [PubMed] 
  14. Cetinözman F, Aksoy DY, Elcin G, Yildiz BO. Insulin sensitivity, androgens and isotretionin therapy in women with severe acne. J Dermatolog Treat. 2014;25:119-122. [Crossref]  [PubMed] 
  15. Mercader J, Ribot J, Murano I, Felipe F, Cinti S, Bonet ML, Palou A. Remodeling of white adipose tissue after retinoic acid administration in mice. Endocrinology. 2006;147:5325-5332. [Crossref]  [PubMed] 
  16. Makrantonaki E, Ganceviciene R, Zouboulis C. An update on the role of the sebaceous gland in the pathogenesis of acne. Dermatoendocrinol. 2011;3:41-49. [Crossref]  [PubMed]  [PMC] 
  17. Bakry OA, El Shazly RMA, El Farargy SM, Kotb D. Role of hormones and blood lipids in the pathogenesis of acne vulgaris in non-obese, non-hirsute females. Indian Dermatol Online J. 2014;5:S9-S16. [Crossref]  [PubMed]  [PMC] 
  18. Ekiz O, Balta I, Unlu E, Bulbul Sen B, Rifaioglu EN, Dogramaci C. Assessment of thyroid function and lipid profile in patients with postadolescent acne in a Mediterranean population from Turkey. Int J Dermatol. 2015;54:1376-1381. [Crossref]  [PubMed] 
  19. Stoll D, Binnert C, Mooser V, Tappy L. Short-term administration of isotretinoin elevates plasma triglyceride concentrations without affecting insulin sensitivity in healthy humans. Metabolism. 2004;53:4-10. [Crossref]  [PubMed] 
  20. Makrantonaki E, Vogel K, Fimmel S, Oeff M, Seltmann H, Zouboulis CC. Interplay of IGF-I and 17beta-estradiol at age-specific levels in human sebocytes and fibroblasts in vitro. Exp Gerontol. 2008;43:939-946. [Crossref]  [PubMed] 
  21. Smith TM, Gilliland K, Clawson GA, Thiboutot D. IGF-1 induces SREBP-1 expression and lipogenesis in SEB-1 sebocytes via activation of the phosphoinositide 3-kinase/Akt pathway. J Invest Dermatol. 2008;128:1286-1293. [Crossref]  [PubMed]  [PMC] 
  22. Rosignoli C, Nicolas JC, Jomard A, Michel S. Involvement of the SREBP pathway in the mode of action of androgens in sebaceous glands in vivo. Exp Dermatol. 2003;12:480-489. [Crossref]  [PubMed] 
  23. Rosenfield RL, Deplewski D. Role of androgens in the developmental biology of the pilosebaceous unit. Am J Med. 1995;98:80S-88S. [Crossref]  [PubMed] 
  24. Aizawa H, Niimura M. Elevated serum insulin-like growth factor-1 (IGF-1) levels in women with postadolescent acne. J Dermatol. 1995;22:249-252. [Crossref]  [PubMed] 
  25. Stewart ME, Downing DT, Cook JS, Hansen, JR, Strauss JS. Sebaceous gland activity and serum dehydroepiandrostreone sulfate levels in boys and girls. Arch Dermatol. 1992;128:1345-1348. [Crossref]  [PubMed] 
  26. Cappel M, Mauger D, Thiboutot D. Correlation between serum levels of insulin-like growth factor 1, dehydroepiandrosterone sulfate, and dihydrotestosterone and acne lesion counts in adult women. Arch Dermatol. 2005;141:333-338. [Crossref]  [PubMed] 
  27. Lucky AW, Biro FM, Simbartl LA, Morrison JA, Sorg NW. Predictors of severity of acne vulgaris in young adolescent girls: results of a five-year longitudinal study. J Pediatr. 1997;130:30-39. [Crossref]  [PubMed] 
  28. Genazzani AD, Stomati M, Strucchi C, Puccetti S, Luisi S, Genazzani AR. Oral dehydroepiandrosterone supplementation modulates spontaneous and growth hormone-releasing hormone-induced growth hormone and insulin-like growth factor-1 secretion in early and late postmenopausal women. Fertil Steril. 2001;76:241-248. [Crossref]  [PubMed] 
  29. Azziz R, Deal CL, Potter HD, Gargosky SE, Rosenfeld RG. Regulation of extragonadal insulin-like growth factor-binding protein-3 by testosterone in oophorectomized women. J Clin Endocrinol Metab. 1994;79:1747-1751. [Crossref]  [PubMed] 
  30. Yanase T, Fan W. Modification of androgen receptor function by IGF-1 signaling implications in the mechanism of refractory prostate carcinoma. Vitam Horm. 2009;80:649-666. [Crossref]  [PubMed] 
  31. Melnik BC. Isotretinoin and FoxO1: a scientific hypothesis. Dermatoendocrinol. 2011;3:141-165. [Crossref]  [PubMed]  [PMC] 
  32. Chen HC, Smith SJ, Tow B, Elias PM, Farese Jr RV. Leptin modulates the effects of acyl CoA:diacylglycerol acyltransferase deficiency on murine fur and sebaceous glands. J Clin Invest. 2002;109:175-181. [Crossref]  [PubMed] 
  33. Lawrence D, Shaw M, Katz M. Elevated free testosterone concentration in men and women with acne vulgaris. Clin Exp Dermatol. 1986;11:263-273. [Crossref]  [PubMed] 
  34. Ju Q, Tao T, Hu T, Karadağ AS, Al-Khuzaei S, Chen W. Sex hormones and acne. Clin Dermatol. 2017;35:130-137. [Crossref]  [PubMed] 
  35. Zouboulis CC, Seltmann H, Hiroi N, Chen W, Young M, Oeff M, Scherbaum WA, Orfanos CE, McCann SM, Bornstein SR. Corticotropin-releasing hormone: an autocrine hormone that promotes lipogenesis in human sebocytes. Proc Natl Acad Sci USA. 2002;99:7148-7153. [Crossref]  [PubMed]  [PMC] 
  36. Thiboutot D, Gollnick H, Bettoli V, Dréno B, Kang S, Leyden JJ, Shalita AR, Lozada VT, Berson D, Finlay A, Goh CL, Herane MI, Kaminsky A, Kubba R, Layton A, Miyachi Y, Perez M, Martin JP, Ramos-E-Silva M, See JA, Shear N, Wolf Jr J, Global Alliance to Improve Outcomes in Acne. New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group. J Am Acad Dermatol. 2009;60:S1-50. [Crossref]  [PubMed] 
  37. Akema T, Chiba A, Oshida M, Kimura F, Toyoda J. Permissive role of corticotropin-releasing factor in the acute stress-induced prolactin release in female rats. Neurosci Lett. 1995;198:146-148. [Crossref]  [PubMed] 
  38. Cong TX, Hao D, Wen X, Li XH, He G, Jiang X. From pathogenesis of acne vulgaris to anti-acne agents. Arch Dermatol Res. 2019;311:337-349. [Crossref]  [PubMed]